Filing Details
- Accession Number:
- 0001185185-11-000832
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-06-02 12:07:30
- Reporting Period:
- 2011-06-01
- Filing Date:
- 2011-06-02
- Accepted Time:
- 2011-06-02 12:07:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1418133 | Biostar Pharmaceuticals Inc. | BSPM | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1459183 | Ronghua Wang | C/O Biostar Pharmaceuticals, Inc. Shiji Avenue Xianyang City, Shaanxi Prov. F4 712000 | Chairman, Ceo | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-06-01 | 1 | $1.30 | 8,968,062 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-06-01 | 1,811 | $1.31 | 8,969,873 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-06-01 | 2,500 | $1.32 | 8,972,373 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-06-01 | 1,700 | $1.33 | 8,974,073 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-06-01 | 1,700 | $1.35 | 8,975,773 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-06-01 | 1,300 | $1.36 | 8,977,073 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-06-01 | 200 | $1.37 | 8,977,273 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-06-01 | 100 | $1.38 | 8,977,373 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- Purchase made pursuant to the stock repurchase plan of the Reporting Person as previously approved by the Board of Directors.